BioPharma in 2024: At a Crossroads

Supporting the Life Sciences Industry at an Inflection Point

This fourth edition of FTI Consulting’s Healthcare and Life Sciences Outlook Survey sees healthcare and biotechnology organizations facing a transition point. Despite being less optimistic about the industry overall in 2024 compared to previous years and expressing concerns about economic and political uncertainty, the 250 industry leaders we surveyed still highlighted a number of game-changing opportunities for the sector in the year ahead. One potential bright spot for 2024: the transformational impact that technology and artificial intelligence (“AI”) are expected to have on the drug development process and life sciences more broadly.

Click here to download the full report